<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770417</url>
  </required_header>
  <id_info>
    <org_study_id>BACOPD</org_study_id>
    <nct_id>NCT02770417</nct_id>
  </id_info>
  <brief_title>Oral β-Alanine Supplementation in Patients With COPD</brief_title>
  <acronym>BACOPD</acronym>
  <official_title>Oral β-Alanine Supplementation in Patients With COPD: Structural, Metabolic and Functional Adaptations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary evidence suggest that patients with chronic obstructive pulmonary disease (COPD)
      suffer from lower-limb muscle dysfunction. This may, at least in part, be due to a
      combination of physical inactivity and muscle oxidative stress. Pilot data (not published)
      clearly show that patients with COPD have significantly lower carnosine, which is a pH
      (acidity-basicity level) buffer and antioxidant, levels in the m. vastus lateralis compared
      to healthy subjects. Beta-alanine supplementation has shown to increase muscle carnosine in
      trained and untrained healthy subjects. This study will assess if muscle carnosine can be
      augmented by beta-alanine supplementation in 40 COPD patients (20 patients receive
      beta-alanine, 20 patients receive placebo). 10 healthy elderly controls will also be assessed
      to compare baseline muscle carnosine levels.

      The aims of this study are to:

        1. Investigate baseline muscle carnosine levels to confirm the pilot data in a larger
           sample of patients with COPD compared with healthy elderly subjects

        2. Investigate if beta-alanine supplementation augments muscle carnosine in COPD patients
           and whether it has an influence on exercise capacity, lower-limb muscle function and
           quality of life

        3. To investigate baseline and post supplementation structural and metabolic muscle
           characteristics and markers of oxidative stress and inflammation in COPD patients and
           it's association with muscle carnosine levels
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle carnosine</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of high pressure liquid chromatography(HPLC)-analysis of a muscle biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximal exercise capacity</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of an incremental maximal cycle test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>submaximal exercise capacity</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of a constant-work rate cycle test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional exercise test 1</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of a 6 minutes walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercise test 2</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of a 4 meter gait test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function quadriceps</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of measuring quadriceps (isometric and isokinetic knee extension-flexion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory muscle function</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of measuring respiratory muscle strength (maximal inspiratory and expiratory pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle function hand grip</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of measuring hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle characteristics</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>Structural and metabolic parameters will be measured with dedicated methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters submaximal exercise test</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of obtaining venous blood before, during and after the constant-work rate cycle test. Blood parameters will be measured with dedicated methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters fasted state</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of obtaining fasting venous blood. Blood parameters will be measured with dedicated methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood parameters maximal exercise test</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of obtaining venous blood before and after the maximal cycle test. Blood parameters will be measured with dedicated methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of Charlson Morbidity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities: ankle-brachial pressure index</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of ankle-brachial pressure index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities blood pressure</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of resting systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities body composition 1</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of bio-electrical impedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities body composition 2</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of whole body dual X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: anxiety and depression</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of the &quot;Hospital Anxiety and Depression Scale&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: fatigue</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of the &quot;Multidimensional Fatigue Inventory&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: dyspnea</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of the &quot; Modified Medical Research Council (MMRC) dyspnea grade&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: general</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of the &quot;Euroqol 5 dimensions (EQ-5D) generic questionnaire&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: COPD</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of the &quot;COPD assessment test&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity: accelerometer</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of physical activity monitoring via Actigraph (accelerometer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity: questionnaire 1</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of physical activity monitoring via &quot;Behavioural Regulation in Exercise Questionnaire&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity: questionnaire 2</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of physical activity monitoring via &quot;Modified Baecke questionnaire&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of general pulmonary function (spirometry, long volumes, diffusion capacity for carbon monoxide).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart function</measure>
    <time_frame>change from baseline to 12 weeks</time_frame>
    <description>by means of resting ECG testing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>COPD (beta-alanine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>beta-alanine</intervention_name>
    <description>Patients receive beta-alanine</description>
    <arm_group_label>COPD (beta-alanine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients receive placebo</description>
    <arm_group_label>COPD (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>Healthy controls will be assessed to compare baseline muscle carnosine levels</description>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD: diagnosis of moderate to very severe COPD according to Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) guidelines

          -  Healthy controls: forced expiratory volume at one second/forced vital capacity
             (FEV1/FVC) &gt; 0.7, matched for age and gender, ratio smokers:non-smokers (1:1)

        Exclusion Criteria:

          -  The presence of known instable cardiac disease

          -  neurological disease and/or musculoskeletal disease that preclude safe participation
             in an exercise test

          -  a history of drugs/alcohol abuse

          -  vegetarianism

          -  inability to understand the Flemish language.

        COPD-specific exclusion criteria:

          -  COPD exacerbation and/or hospitalization in the last 6 weeks

          -  participation in pulmonary rehabilitation in the previous 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn Spruit, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jana De Brandt, drs</last_name>
    <role>Study Chair</role>
    <affiliation>Hasselt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martijn Spruit, prof. dr.</last_name>
    <email>martijn.spruit@uhasselt.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana De Brandt, drs.</last_name>
    <email>jana.debrandt@uhasselt.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jessa Ziekenhuis (ReGo)</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana De Brandt, drs.</last_name>
      <email>jana.debrandt@uhasselt.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>Martijn Spruit</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

